Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
VIGL

VIGL - Vigil Neuroscience, Inc. Stock Price, Fair Value and News

3.88USD+0.02 (+0.52%)Market Closed

Market Summary

VIGL
USD3.88+0.02
Market Closed
0.52%

VIGL Stock Price

View Fullscreen

VIGL RSI Chart

VIGL Valuation

Market Cap

145.8M

Price/Earnings (Trailing)

-1.76

Price/Free Cashflow

-2.06

VIGL Price/Earnings (Trailing)

VIGL Profitability

Return on Equity

-79.77%

Return on Assets

-66.19%

Free Cashflow Yield

-48.5%

VIGL Fundamentals

VIGL Earnings

Earnings (TTM)

-82.8M

Earnings Growth (Yr)

-0.73%

Earnings Growth (Qtr)

10.07%

Breaking Down VIGL Revenue

Last 7 days

-8.5%

Last 30 days

6.9%

Last 90 days

39.1%

Trailing 12 Months

-59.6%

How does VIGL drawdown profile look like?

VIGL Financial Health

Current Ratio

12.38

VIGL Investor Care

Shares Dilution (1Y)

5.32%

Diluted EPS (TTM)

-2.12

Tracking the Latest Insider Buys and Sells of Vigil Neuroscience, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 20, 2023
magovcevic-liebisch ivana
bought
15,000
3.75
4,000
president and ceo
Nov 18, 2022
papapetropoulos spyros
acquired
567
1.89
300
chief medical officer
Nov 18, 2022
papapetropoulos spyros
sold
-4,200
14.00
-300
chief medical officer
May 17, 2022
thorp clay
bought
44,189
2.9671
14,893
-
May 16, 2022
thorp clay
bought
60,221
2.7622
21,802
-
May 05, 2022
thackaberry evan
bought
6,000
4.00
1,500
svp, head of early development
May 03, 2022
magovcevic-liebisch ivana
bought
3,940
3.9402
1,000
president and ceo
May 03, 2022
verni christopher
bought
15,074
3.7686
4,000
general counsel
May 03, 2022
papapetropoulos spyros
bought
13,591
3.3978
4,000
chief medical officer
May 03, 2022
ziolkowski jennifer lynn
bought
15,097
3.7744
4,000
chief financial officer

1–10 of 34

Which funds bought or sold VIGL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 17, 2024
Artal Group S.A.
unchanged
-
54,161
6,176,160
0.16%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
sold off
-100
-8,940
-
-%
May 16, 2024
JANE STREET GROUP, LLC
sold off
-100
-34,402
-
-%
May 15, 2024
Rock Springs Capital Management LP
unchanged
-
14,159
1,609,380
0.04%
May 15, 2024
PRELUDE CAPITAL MANAGEMENT, LLC
new
-
69,486
69,486
-%
May 15, 2024
DAFNA Capital Management LLC
unchanged
-
2,154
244,889
0.06%
May 15, 2024
683 Capital Management, LLC
new
-
3,392,610
3,392,610
0.25%
May 15, 2024
TWO SIGMA ADVISERS, LP
new
-
82,181
82,181
-%
May 15, 2024
ArrowMark Colorado Holdings LLC
unchanged
-
8,684
987,059
0.01%
May 15, 2024
SPHERA FUNDS MANAGEMENT LTD.
added
223
4,092,010
5,900,710
0.83%

1–10 of 50

Are Funds Buying or Selling VIGL?

Are funds buying VIGL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VIGL
No. of Funds

Unveiling Vigil Neuroscience, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 29, 2024
artal international s.c.a.
4.9%
1,811,191
SC 13G/A
Feb 14, 2024
citadel advisors llc
6.0%
6
SC 13G/A
Feb 14, 2024
deep track capital, lp
9.62%
3,649,726
SC 13G/A
Feb 12, 2024
flynn james e
3.27%
1,173,523
SC 13G/A
Feb 09, 2024
artal international s.c.a.
5.0%
1,811,191
SC 13G/A
Feb 14, 2023
citadel advisors llc
6.1%
6
SC 13G/A
Feb 14, 2023
hatteras venture partners vi, lp
4.4%
1,562,578
SC 13G
Feb 13, 2023
artal international s.c.a.
6.3%
2,243,352
SC 13G/A
Feb 10, 2023
flynn james e
5.77%
2,052,010
SC 13G/A
Feb 10, 2023
vida ventures gp iii, l.l.c.
14.1%
5,015,929
SC 13D

Recent SEC filings of Vigil Neuroscience, Inc.

View All Filings
Date Filed Form Type Document
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 06, 2024
8-K
Current Report
May 07, 2024
4
Insider Trading
May 07, 2024
10-Q
Quarterly Report

Peers (Alternatives to Vigil Neuroscience, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
52.5B
6.8B
-17.75% 15.65%
-8.8
7.67
-64.45% -224.75%
28.2B
2.0B
50.83% 15.66%
-84.91
14.07
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.2B
2.5B
12.78% -8.91%
78.69
6.54
13.74% 186.89%
14.3B
3.8B
11.22% 2.07%
19.2
3.8
8.58% 129.81%
MID-CAP
4.7B
524.1M
-5.39% -54.95%
-11.17
8.9
394.93% 39.61%
4.3B
107.9M
-17.68% 46.87%
-7.87
48.09
54.84% -28.31%
3.7B
251.0M
4.40% -10.91%
-12.58
14.85
73.58% -86.73%
3.4B
240.7M
9.49% -22.70%
-7.15
12.77
-1.03% -213.92%
2.6B
813.8M
4.41% -35.25%
-1.5K
3.22
56.43% 98.83%
2.0B
996.6M
-9.61% 109.10%
-4.93
1.97
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.09% 16.96%
27.9
4.42
60.38% -34.49%
464.6M
881.7K
-3.44% 394.54%
-13.76
481.06
-77.61% 33.36%
206.5M
4.2M
-27.55% 54.46%
-1.65
49.65
-66.30% 48.24%
18.0M
2.1M
-4.57% 211.94%
-0.78
7.61
-13.45% 69.54%

Vigil Neuroscience, Inc. News

Latest updates
MarketBeat22 Jun 202405:43 am

Vigil Neuroscience, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q4
Assets-11.2%125141159175192200216158173102
  Current Assets-12.6%10712214015617219821315617097.00
    Cash Equivalents-0.4%52.0052.0057.0059.0096.0018820414916392.00
  Net PPE-6.2%2.002.002.002.002.001.001.001.001.000.00
Liabilities-13.5%21.0025.0023.0022.0021.0011.0010.007.007.0010.00
  Current Liabilities-26.2%9.0012.0010.008.007.0011.0010.007.007.0010.00
Shareholder's Equity-10.7%104116136154171189206151166-
  Retained Earnings-9.0%-242-222-200-180-159-140-121-104-87.16-71.83
  Additional Paid-In Capital2.2%3473393363343313293282552532.00
Shares Outstanding4.7%38.0036.0036.0036.0039.0036.0033.0028.0028.002.00
Float----233---30.00--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q1
Cashflow From Operations-41.1%-21,881-15,510-17,314-15,353-22,186-17,087-15,925-13,993-18,144-17,347-11,073-6,164-4,763
  Share Based Compensation-7.0%2,3122,4862,4262,2571,7341,5011,4941,4611,021762556434333
Cashflow From Investing54.5%16,46610,65515,314-22,103-69,004-272-416-91.00-142----
Cashflow From Financing9681.1%5,18453.0053.0057920310171,292-32890,190-1,86289,704--
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

VIGL Income Statement

2024-03-31
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:  
Research and development[1]$ 14,326$ 13,834
General and administrative7,0896,941
Total operating expenses21,41520,775
Loss from operations(21,415)(20,775)
Other income (expense):  
Interest income, net1,477985
Other income (expense), net(2)(5)
Total other income, net1,475980
Net loss$ (19,940)$ (19,795)
Net loss per share attributable to common stockholders, basic$ (0.5)$ (0.51)
Net loss per share attributable to common stockholders, diluted$ (0.5)$ (0.51)
Weighted-average common shares outstanding, basic39,864,11138,546,012
Weighted-average common shares outstanding, diluted39,864,11138,546,012
Comprehensive loss:  
Net loss$ (19,940)$ (19,795)
Unrealized gain (loss) on available for sale securities(25)106
Total comprehensive loss$ (19,965)$ (19,689)
[1]Includes related party amounts of $0 for the three months ended March 31, 2024, and $43 for the three months ended March 31, 2023 (see Note 10).

VIGL Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 51,761$ 51,992
Marketable securities49,88465,948
Prepaid expenses and other current assets4,8983,967
Total current assets106,543121,907
Property and equipment, net1,6371,745
Operating lease right-of-use assets15,80116,147
Financing lease right-of-use assets4449
Restricted cash927927
Other assets12683
Total assets125,078140,858
Current liabilities:  
Accounts payable1,4911,946
Accrued expenses and other current liabilities6,1758,810
Operating lease liabilities937905
Total current liabilities8,60311,661
Operating lease liabilities, net of current portion12,69312,945
Total liabilities21,29624,606
Commitments and contingencies (Note 11)
Stockholders' equity:  
Undesignated preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023, respectively; 0 share issued and outstanding at March 31, 2024 and December 31, 2023, respectively
Common stock, $0.0001 par value; 150,000,000 shares authorized at March 31, 2024 and December 31, 2023; 37,628,635 shares issued as of March 31, 2024 and 35,929,035 shares issued as of December 31, 2023; and 37,584,312 shares outstanding as of March 31, 2024 and 35,884,712 shares outstanding as of December 31, 202344
Additional paid-in capital346,520339,025
Accumulated other comprehensive income(30)(5)
Accumulated deficit(242,712)(222,772)
Total stockholders' equity103,782116,252
Total liabilities and stockholders' equity$ 125,078$ 140,858
VIGL
Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101, a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 proof-of-concept trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also conducting IND-enabling studies with a novel small molecule TREM2 agonist program to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Watertown, Massachusetts.
 CEO
 WEBSITEvigilneuro.com
 INDUSTRYBiotechnology
 EMPLOYEES61

Vigil Neuroscience, Inc. Frequently Asked Questions


What is the ticker symbol for Vigil Neuroscience, Inc.? What does VIGL stand for in stocks?

VIGL is the stock ticker symbol of Vigil Neuroscience, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vigil Neuroscience, Inc. (VIGL)?

As of Mon Jun 24 2024, market cap of Vigil Neuroscience, Inc. is 145.83 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VIGL stock?

You can check VIGL's fair value in chart for subscribers.

What is the fair value of VIGL stock?

You can check VIGL's fair value in chart for subscribers. The fair value of Vigil Neuroscience, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vigil Neuroscience, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VIGL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vigil Neuroscience, Inc. a good stock to buy?

The fair value guage provides a quick view whether VIGL is over valued or under valued. Whether Vigil Neuroscience, Inc. is cheap or expensive depends on the assumptions which impact Vigil Neuroscience, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VIGL.